What Вальдоксан Treats: Main Uses and Benefits

The primary therapeutic role of Вальдоксан (Agomelatine) is the management of Major Depressive Episodes (MDE) in adults. The support it provides addresses both the core emotional symptoms of depression and the related disturbances in the patient’s sleep-wake patterns.

Treatment of Core Depressive Symptoms

This domain covers the central symptoms of the Major Depressive Episode, including the persistent low mood, deep sadness, and the loss of interest or pleasure (anhedonia). The medication is applied in clinical settings that involve acute or unstable symptom patterns. Вальдоксан is indicated for the treatment of Major Depressive Episodes in adults, a context where it generally provides support that helps ease the overall burden of symptoms. The use of this medicine is associated with supporting emotional balance and symptomatic relief during the acute depressive phase.

Restoration of Disturbed Sleep Patterns

Вальдоксан is commonly applied in situations where depression is complicated by significant disturbances in the sleep-wake cycle, such as difficulty falling asleep or poor sleep quality. Its therapeutic application is intended to assist with an improvement in sleep continuity and quality, which generally helps improve day-to-day comfort during symptomatic periods and contributes to easing the overall symptom load. This approach generally supports long-term emotional balance and stability.

“The use of this medicine is associated with supporting emotional balance and symptomatic relief during the acute depressive phase.”

Quick Fact: Relief for Depressive Sleep Disturbances The medication is commonly used when symptoms related to sleep patterns—such as difficulty with sleep timing or quality—are highly disruptive and interfere with daily functioning.

Regulatory References

1. European Medicines Agency therapeutic overview

This section outlines the official eligibility and non-eligibility rules for Вальдоксан (Agomelatine), based strictly on government regulatory documents.

---

Contraindications (Must Not Use)

Use is absolutely prohibited for patients who:

• Have known hypersensitivity to agomelatine or any excipients.
• Have hepatic impairment (active liver disease or cirrhosis).
• Have baseline serum transaminase levels ( ALT and/or AST) exceeding 3X the Upper Limit of Normal ( ULN).
• Are taking concomitant potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin).

---

Age and Special Population Restrictions

Population	Regulatory Status
Children/Adolescents (<18)	Not recommended (safety/efficacy not established).
Older Adults ( ge 75 years)	Should not be used (no effect is documented).
Elderly with Dementia	Should not be used (safety/efficacy not established).
Pregnancy/Lactation	Caution advised during pregnancy; breastfeeding must be discontinued if treatment is necessary.

---

Conditional Use and Caution

Special caution and surveillance are required for patients with a history of mania or bipolar disorder, moderate or severe renal impairment, or those with hepatic injury risk factors like obesity, diabetes, or substantial alcohol intake.

Interactions with other medicines and products

Regulatory documentation establishes specific interaction patterns for Вальдоксан (Agomelatine) based primarily on its metabolism by the hepatic enzyme CYP1A2.

Contraindicated and High-Risk Combinations

Co-administration with potent CYP1A2 inhibitors is formally contraindicated due to the risk of significantly increased systemic exposure to agomelatine. This restriction specifically includes the medicinal products Fluvoxamine and Ciprofloxacin. Fluvoxamine, in particular, has been documented to increase agomelatine exposure up to 60-fold.

Moderate CYP1A2 inhibitors—such as Oestrogens (when used as hormone replacement therapy) and Propranolol—are subject to caution, as their co-administration also results in a several-fold increase in agomelatine exposure.

Interaction Type	Interacting Substance	Official Restriction
Potent CYP1A2 Inhibition	Fluvoxamine, Ciprofloxacin	Contraindicated
Moderate CYP1A2 Inhibition	Oestrogens, Propranolol	Use with Caution

Other Documented Interactions

Substances that induce CYP1A2 may decrease the bioavailability of agomelatine. This includes the medicinal product Rifampicin and the lifestyle factor of heavy smoking (defined as ge 15 cigarettes per day). Furthermore, the official label states that co-administration with alcohol is not advisable, particularly for patients consuming substantial quantities. No pharmacokinetic or pharmacodynamic interactions were found with Benzodiazepines or Lithium.

How Вальдоксан Works

The action of Agomelatine is defined by a synergistic dual mechanism, engaging two distinct receptor systems to exert a dual physiological effect on biological timing and neurochemical balance.

---

Chronobiotic Modulation and Receptor Agonism

This domain addresses the drug's role in regulating the sleep-wake cycle. Agomelatine acts as an agonist (activator) on the MT1 and MT2 melatonin receptors within the brain's central clock. This molecular interaction directly modulates the timing signal of the Suprachiasmatic Nucleus (SCN), resulting in the resynchronization of biological rhythms and contributing to the regulation of sleep architecture.

---

Targeted Monoamine Disinhibition

This domain covers the drug's influence on key neurotransmitter systems. Agomelatine functions as an antagonist (blocker) of the 5-HT2C serotonin receptor. By removing the inhibitory brake exerted by this receptor, the mechanism specifically promotes the enhanced release of Noradrenaline (NA) and Dopamine (DA), concentrated in the frontal cortex. This targeted disinhibition modulates neuronal activity and supports the adjustment of neurochemical balance in relevant neuronal circuits.

Administration Protocol for Вальдоксан (Agomelatine)

Вальдоксан is provided as a 25 mg film-coated tablet for oral administration.

Dosing and Scheduling

The standard regimen involves taking the medicine once daily at a specific time: at bedtime in the evening. This timed administration is a condition of use and is permissible with or without food. Treatment is initiated at a dose of 25 mg. A dose increase to the maximum of 50 mg may be considered only after the initial 25 mg regimen has been maintained for a minimum of two weeks without sufficient symptomatic response.

Course Duration and Procedural Rules

Treatment protocols typically involve continuation for at least 6 months following the achievement of symptom stabilization. A key procedural element is that no dosage tapering is required upon discontinuation of the medicine. In the event a dose is missed, the protocol is to take the next dose at the usual time and not take a double dose to compensate.

Usage Restrictions

There are clear restrictions on use for specific populations. The medicine is not to be used in patients 75 years of age or older or in individuals with hepatic impairment. Use is also not recommended for patients under 18 years of age.

Summary of Clinical Trials

Clinical evidence for the active substance, agomelatine, primarily derives from randomized, placebo-controlled trials (RCTs) involving adults with major depressive disorder (MDD).

Studies have consistently explored the drug’s potential to influence depressive symptoms. A systematic review and network meta-analysis that compared 21 antidepressants indicated that agomelatine was among the most effective and tolerable treatments for the acute phase of MDD. However, some individual meta-analyses have suggested that the clinical difference between agomelatine and placebo may be modest, particularly when analyzing both published and unpublished trial data.

---

Key Areas of Focus in Research

Research has concentrated on several specific areas:

• Acute Treatment: Multiple short-term studies (6 to 12 weeks) have examined whether agomelatine shows a statistically significant effect over placebo in improving scores on standard depression rating scales (e.g., HAM-D).
• Relapse Prevention: Long-term trials have explored the use of agomelatine in maintaining symptom control in patients who had already responded to the treatment, with some studies showing a reduced risk of relapse compared to placebo over 24-26 weeks.
• Circadian Rhythm and Sleep: Given its unique mechanism as a melatonin (MT1/MT2) receptor agonist and serotonin (5-HT2C) receptor antagonist, research suggests agomelatine may help resynchronize altered circadian rhythms and improve sleep quality in depressed patients, often without the sleepiness or sexual side effects sometimes associated with other antidepressants.

---

Safety and Tolerability

Clinical trials report that agomelatine is generally well-tolerated. The incidence of discontinuation due to adverse events in trials comparing agomelatine to placebo was found to be similar. However, a crucial safety finding from the research is the potential for liver enzyme elevation (transaminases), which requires routine liver function monitoring throughout treatment, particularly at initiation and upon dosage adjustment.

Key Studies & References Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials

Common questions about Вальдоксан (FAQ)

Q: Does Вальдоксан have withdrawal symptoms when stopping use?

A: Official documentation states that no dosage tapering is needed when discontinuing this medicine. However, some patients have reported discontinuation symptoms, such as dizziness or anxiety, although these effects were usually described as mild to moderate and transient.

Q: Can Вальдоксан cause drowsiness during the day?

A: Yes, regulatory product information lists sleepiness (somnolence) as a common side effect of this medicine. Dizziness is also listed as a common effect. Patients are generally advised to be aware of potential effects that could impact concentration.

Q: Does Вальдоксан affect sexual function?

A: Sexual dysfunction is not listed among the very common, common, uncommon, or rare side effects in the main safety tables of the regulatory documents. Sexual dysfunction is not listed among the frequency-classified adverse effects in the official product information.

Q: What happens if a dose of Вальдоксан is missed?

A: Official regulatory instructions advise that if a dose is forgotten, the patient should not take the missed dose. Instead, the patient should take the next dose at the usual scheduled time.

Q: What kind of side effects are generally mild when starting Вальдоксан?

A: According to official information, adverse reactions were generally mild or moderate and tended to occur within the first two weeks of treatment. Common reactions reported in this early phase include transient effects such as headache, nausea, and dizziness.

Q: Does Вальдоксан interact with alcohol?

A: Official labeling states that the co-administration of this medicine with alcohol is not advisable. This caution is particularly emphasized for patients who consume substantial quantities of alcohol, due to the recognized risk of liver injury.

Q: Can Вальдоксан be used by people who have anxiety?

A: The medicine is authorized only for the treatment of major depressive episodes in adults. Anxiety is listed as a common adverse reaction in the side effects tables, meaning it was reported in up to 1 in 10 people during clinical trials.

Q: Is Вальдоксан approved for long-term use?

A: Treatment protocols advise that the medicine should be continued for at least six months following the achievement of symptom stabilization. Long-term studies have explored its use for relapse prevention over periods of several months.

Q: Is Вальдоксан available in generic form?

A: The active substance in Вальдоксан is Agomelatine. The availability of generic forms of Agomelatine depends on the patent status and specific local drug regulations in a given country or territory.

Q: What happens if Вальдоксан is taken longer than expected?

A: The duration of treatment beyond the minimum period is subject to ongoing review by a healthcare provider. Regulatory guidelines emphasize that continued, periodic monitoring of liver function tests is required for prolonged use.

Q: Can Вальдоксан affect a person's driving ability?

A: Official information explicitly cautions patients that they might experience dizziness or sleepiness (somnolence) while using this medicine. The regulatory documents suggest patients should ensure their reactions are normal before engaging in activities like driving or operating machinery.

Q: Can Вальдоксан be taken by people with kidney issues?

A: Official documents state that caution should be exercised when the medicine is prescribed to patients who have moderate or severe renal (kidney) impairment. No significant change in drug exposure was noted in those with severe kidney impairment.

Q: Is Вальдоксан known for causing weight gain?

A: According to the official list of side effects, 'weight increased' is classified as a common adverse reaction, meaning it may affect up to 1 in 10 people. Conversely, 'weight decreased' is listed as an uncommon side effect.

Q: Can Вальдоксан affect concentration or memory?

A: Specific effects on concentration or memory are not listed as adverse reactions in the main safety tables. However, common side effects reported include dizziness and somnolence (sleepiness), which are known to potentially affect attention.

Q: Does Вальдоксан have abuse or dependence potential?

A: Regulatory documents do not specifically list abuse or dependence potential. It is noted in the official product information that a dosage taper is not required when discontinuing the medicine.

Q: Is Вальдоксан suitable for people with bipolar disorder?

A: Official warnings state that caution should be exercised when administering this medicine to patients with a history of bipolar disorder, mania, or hypomania. Official guidelines state that treatment must be discontinued if a patient develops manic symptoms.

Q: Is Вальдоксан used for purposes other than depression?

A: The official marketing authorization for this medicine confirms that it is authorized only for the treatment of major depressive episodes in adults. The official authorization covers only the treatment of major depressive episodes in adults.

Q: Does Вальдоксан affect the body's 'internal clock'?

A: Yes, its unique mechanism involves activating the MT1 and MT2 melatonergic receptors in the brain. This action contributes to the resynchronization of disturbed circadian rhythms, which is the scientific term for the body's internal clock.

Q: What is the risk of suicidal thoughts mentioned in relation to Вальдоксан?

A: Suicidal thoughts or behavior is listed as an uncommon adverse reaction. Regulatory information indicates that close supervision is necessary, especially during early treatment and following dose changes, particularly for younger adult populations.

Q: Is Вальдоксан associated with any specific eye-related side effects?

A: Blurred vision is listed as an uncommon side effect in the official regulatory documents. No other specific, severe eye-related effects, such as glaucoma or increased intraocular pressure, are listed in the frequency-classified safety tables.

Q: Is Вальдоксан used for SAD (Seasonal Affective Disorder)?

A: The medicine is authorized only for the treatment of major depressive episodes in adults. Seasonal Affective Disorder, which is a specific diagnosis, is not listed as an approved indication in the official label.

How to Store and Dispose of Valdoxan (Agomelatine)

Storage and disposal instructions for Valdoxan tablets are defined by official regulatory labeling to maintain product stability and safety.

---

Official Storage Requirements

Requirement	Stated Condition
Temperature	Does not require any special temperature storage conditions.
Protection	Store in the original package to protect from moisture.
Shelf Life	The labeled shelf life of the product is 3 years.
Safety	Must be kept out of the reach and sight of children.

Disposal

Any unused or expired Вальдоксан must be disposed of in accordance with local requirements. This instruction ensures that the medicine is not improperly discarded through household trash or wastewater systems.